Three recent trials are ongoing: the trials with ClinicalTrials.gov Identifier NCT03161756 (Evaluation of Denosumab in Combination with Immune Checkpoint Inhibitors in Patients with Unresectable or Metastatic Melanoma (CHARLI)) [89], NCT03280667 (Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma (KEYPAD)) [90] and NCT03620019 (Denosumab + PD-1 in Subjects with Stage III/IV Melanoma). This evidence concerns the gene PDCD1 and melanoma.